“The translational impact and nature of the work that was being presented were outstanding. You get a lot of insights from your peers regarding their experience interacting with the regulatory agencies” – ONK Tx

The 9^th Innate Killer Summit is designed for experts striving to realize the clinical potential of NK–based therapies from early discovery to later stages in the clinic through 3 dedicated tracks of content: Pre-clinical, Clinical Translation, CMC & Process Development.

Specifically focussing on advancing NK engager, bispecific, cell therapy, and combination therapy approaches to improve the clinical durability and streamlining manufacturing. Come together with industry experts to brainstorm best approaches to enhance efficacy and persistence as well as reduce the cost of production.

Collaborating closely with pioneers such as Dan Kaufman, Evren Alici, and industry experts from Zelluna Immunotherapy, Artiva Biotherapeutics, Affimed, Sanofi, Immunity Bio, Cytovia (to name a few!) to ensure the critical priorities of the field are captured. Join to gain practical takeaways for novel techniques in engineering NK cells while preserving cell fitness, best practice clinical trial design methods, benefits of feeder-free cell expansion and many more!

Ranging from a jam-packed pre-conference workshop day with 6 different workshops and a bootcamp ranging from preclinical to CMC and process development. Also up for offer are 10+ plenary talks across the main conference days where experts will guide you through the current cell therapy landscape, an industry leaders annual briefing, a range of clinical data presentations, and an investors panel!